- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report offers an overview of the market trends, drivers, and barriers with respect to the USA HER-2 Targeted Drugs for Breast Cancer market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA HER-2 Targeted Drugs for Breast Cancer market. Detailed analysis of key players, along with key growth strategies adopted by HER-2 Targeted Drugs for Breast Cancer industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Beacon Pharmaceuticals Limited
Hengrui Medicine
GlaxoSmithKline
Hetero Drugs
Puma Biotechnology
Novartis
Chugai Pharmaceutical
Roche
CANbridge
Pfizer
By Type:
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Other
By End-User:
Hospital
Clinic
Drug Center
Other
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of HER-2 Targeted Drugs for Breast Cancer Market
-
1.3 Market Segment by Type
-
1.3.1 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Trastuzumab from 2016 to 2027
-
1.3.2 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Pertuzumab from 2016 to 2027
-
1.3.3 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Lapatinib from 2016 to 2027
-
1.3.4 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Neratinib from 2016 to 2027
-
1.3.5 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Trastuzumab Emtansine from 2016 to 2027
-
1.3.6 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Pyrotinib from 2016 to 2027
-
1.3.7 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Other from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Hospital from 2016 to 2027
-
1.4.2 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Clinic from 2016 to 2027
-
1.4.3 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Drug Center from 2016 to 2027
-
1.4.4 USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Other from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of HER-2 Targeted Drugs for Breast Cancer Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of HER-2 Targeted Drugs for Breast Cancer by Major Types
-
3.4.1 Market Size and Growth Rate of Trastuzumab
-
3.4.2 Market Size and Growth Rate of Pertuzumab
-
3.4.3 Market Size and Growth Rate of Lapatinib
-
3.4.4 Market Size and Growth Rate of Neratinib
-
3.4.5 Market Size and Growth Rate of Trastuzumab Emtansine
-
3.4.6 Market Size and Growth Rate of Pyrotinib
-
3.4.7 Market Size and Growth Rate of Other
4 Segmentation of HER-2 Targeted Drugs for Breast Cancer Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of HER-2 Targeted Drugs for Breast Cancer by Major End-Users
-
4.4.1 Market Size and Growth Rate of HER-2 Targeted Drugs for Breast Cancer in Hospital
-
4.4.2 Market Size and Growth Rate of HER-2 Targeted Drugs for Breast Cancer in Clinic
-
4.4.3 Market Size and Growth Rate of HER-2 Targeted Drugs for Breast Cancer in Drug Center
-
4.4.4 Market Size and Growth Rate of HER-2 Targeted Drugs for Breast Cancer in Other
5 Market Analysis by Regions
-
5.1 USA HER-2 Targeted Drugs for Breast Cancer Production Analysis by Regions
-
5.2 USA HER-2 Targeted Drugs for Breast Cancer Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis
-
6.1 West USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major Types
-
6.2 West USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major End-Users
7 South USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis
-
7.1 South USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major Types
-
7.2 South USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major End-Users
8 Middle West USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis
-
8.1 Middle West USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major Types
-
8.2 Middle West USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major End-Users
9 Northeast USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis
-
9.1 Northeast USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major Types
-
9.2 Northeast USA HER-2 Targeted Drugs for Breast Cancer Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 Beacon Pharmaceuticals Limited
-
10.1.1 Beacon Pharmaceuticals Limited Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Hengrui Medicine
-
10.2.1 Hengrui Medicine Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 GlaxoSmithKline
-
10.3.1 GlaxoSmithKline Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 Hetero Drugs
-
10.4.1 Hetero Drugs Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
-
10.5 Puma Biotechnology
-
10.5.1 Puma Biotechnology Company Profile and Recent Development
-
10.5.2 Market Performance
-
10.5.3 Product and Service Introduction
-
10.6 Novartis
-
10.6.1 Novartis Company Profile and Recent Development
-
10.6.2 Market Performance
-
10.6.3 Product and Service Introduction
-
10.7 Chugai Pharmaceutical
-
10.7.1 Chugai Pharmaceutical Company Profile and Recent Development
-
10.7.2 Market Performance
-
10.7.3 Product and Service Introduction
-
10.8 Roche
-
10.8.1 Roche Company Profile and Recent Development
-
10.8.2 Market Performance
-
10.8.3 Product and Service Introduction
-
10.9 CANbridge
-
10.9.1 CANbridge Company Profile and Recent Development
-
10.9.2 Market Performance
-
10.9.3 Product and Service Introduction
-
10.10 Pfizer
-
10.10.1 Pfizer Company Profile and Recent Development
-
10.10.2 Market Performance
-
10.10.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Trastuzumab from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Pertuzumab from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Lapatinib from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Neratinib from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Trastuzumab Emtansine from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Pyrotinib from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Other from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Hospital from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Clinic from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Drug Center from 2016 to 2027
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Market Size and Growth Rate of Other from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of HER-2 Targeted Drugs for Breast Cancer Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of HER-2 Targeted Drugs for Breast Cancer
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of HER-2 Targeted Drugs for Breast Cancer by Different Types from 2016 to 2027
-
Table Consumption Share of HER-2 Targeted Drugs for Breast Cancer by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Trastuzumab
-
Figure Market Size and Growth Rate of Pertuzumab
-
Figure Market Size and Growth Rate of Lapatinib
-
Figure Market Size and Growth Rate of Neratinib
-
Figure Market Size and Growth Rate of Trastuzumab Emtansine
-
Figure Market Size and Growth Rate of Pyrotinib
-
Figure Market Size and Growth Rate of Other
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of HER-2 Targeted Drugs for Breast Cancer by Different End-Users from 2016 to 2027
-
Table Consumption Share of HER-2 Targeted Drugs for Breast Cancer by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospital
-
Figure Market Size and Growth Rate of Clinic
-
Figure Market Size and Growth Rate of Drug Center
-
Figure Market Size and Growth Rate of Other
-
Table USA HER-2 Targeted Drugs for Breast Cancer Production by Regions
-
Table USA HER-2 Targeted Drugs for Breast Cancer Production Share by Regions
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Production Share by Regions in 2016
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Production Share by Regions in 2021
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Production Share by Regions in 2027
-
Table USA HER-2 Targeted Drugs for Breast Cancer Consumption by Regions
-
Table USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Regions
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Regions in 2016
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Regions in 2021
-
Figure USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Regions in 2027
-
Table West USA HER-2 Targeted Drugs for Breast Cancer Consumption by Types from 2016 to 2027
-
Table West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types from 2016 to 2027
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2016
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2021
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2027
-
Table West USA HER-2 Targeted Drugs for Breast Cancer Consumption by End-Users from 2016 to 2027
-
Table West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users from 2016 to 2027
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2016
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2021
-
Figure West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2027
-
Table South USA HER-2 Targeted Drugs for Breast Cancer Consumption by Types from 2016 to 2027
-
Table South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types from 2016 to 2027
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2016
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2021
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2027
-
Table South USA HER-2 Targeted Drugs for Breast Cancer Consumption by End-Users from 2016 to 2027
-
Table South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users from 2016 to 2027
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2016
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2021
-
Figure South USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2027
-
Table Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption by Types from 2016 to 2027
-
Table Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2016
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2021
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2027
-
Table Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption by End-Users from 2016 to 2027
-
Table Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2016
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2021
-
Figure Middle West USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2027
-
Table Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption by Types from 2016 to 2027
-
Table Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2016
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2021
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by Types in 2027
-
Table Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption by End-Users from 2016 to 2027
-
Table Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2016
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2021
-
Figure Northeast USA HER-2 Targeted Drugs for Breast Cancer Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Beacon Pharmaceuticals Limited
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Beacon Pharmaceuticals Limited
-
Figure Sales and Growth Rate Analysis of Beacon Pharmaceuticals Limited
-
Figure Revenue and Market Share Analysis of Beacon Pharmaceuticals Limited
-
Table Product and Service Introduction of Beacon Pharmaceuticals Limited
-
Table Company Profile and Development Status of Hengrui Medicine
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hengrui Medicine
-
Figure Sales and Growth Rate Analysis of Hengrui Medicine
-
Figure Revenue and Market Share Analysis of Hengrui Medicine
-
Table Product and Service Introduction of Hengrui Medicine
-
Table Company Profile and Development Status of GlaxoSmithKline
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline
-
Figure Sales and Growth Rate Analysis of GlaxoSmithKline
-
Figure Revenue and Market Share Analysis of GlaxoSmithKline
-
Table Product and Service Introduction of GlaxoSmithKline
-
Table Company Profile and Development Status of Hetero Drugs
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hetero Drugs
-
Figure Sales and Growth Rate Analysis of Hetero Drugs
-
Figure Revenue and Market Share Analysis of Hetero Drugs
-
Table Product and Service Introduction of Hetero Drugs
-
Table Company Profile and Development Status of Puma Biotechnology
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Puma Biotechnology
-
Figure Sales and Growth Rate Analysis of Puma Biotechnology
-
Figure Revenue and Market Share Analysis of Puma Biotechnology
-
Table Product and Service Introduction of Puma Biotechnology
-
Table Company Profile and Development Status of Novartis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis
-
Figure Sales and Growth Rate Analysis of Novartis
-
Figure Revenue and Market Share Analysis of Novartis
-
Table Product and Service Introduction of Novartis
-
Table Company Profile and Development Status of Chugai Pharmaceutical
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Chugai Pharmaceutical
-
Figure Sales and Growth Rate Analysis of Chugai Pharmaceutical
-
Figure Revenue and Market Share Analysis of Chugai Pharmaceutical
-
Table Product and Service Introduction of Chugai Pharmaceutical
-
Table Company Profile and Development Status of Roche
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche
-
Figure Sales and Growth Rate Analysis of Roche
-
Figure Revenue and Market Share Analysis of Roche
-
Table Product and Service Introduction of Roche
-
Table Company Profile and Development Status of CANbridge
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of CANbridge
-
Figure Sales and Growth Rate Analysis of CANbridge
-
Figure Revenue and Market Share Analysis of CANbridge
-
Table Product and Service Introduction of CANbridge
-
Table Company Profile and Development Status of Pfizer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer
-
Figure Sales and Growth Rate Analysis of Pfizer
-
Figure Revenue and Market Share Analysis of Pfizer
-
Table Product and Service Introduction of Pfizer
-